News Related to CD34-Positive Cells

Related coverage linked through entity extraction aliases.

CellProthera Prepares Phase III Cardiac Stem Cell Trial, Acquires Delivery Catheter

Mar 18, 2026

CellProthera plans to launch a Phase III trial of its ProtheraCytes stem cell therapy for heart failure patients in Q1 2027, enrolling 300-400 patients across 50 sites. The company acquired a transendocardial catheter from Celyad Oncology for €5 million to enable precise delivery of the therapy.

New Engineering Strategies Boost CAR-NK and CAR-T Cell Therapies Against Cancer

Feb 28, 2026

Recent studies demonstrate significant advances in engineered immune cell therapies, including enhanced CAR-T cells for solid tumors through NR2F6 deletion and mass production of CAR-NK cells from cord blood stem cells capable of generating millions of tumor-killing cells.